TAVR vs SAVR in 2025: A Cardiac Surgeon's Honest Comparison of Aortic Valve Replacement Options

Why the TAVR vs SAVR Decision Is More Complex Than You've Been Told

If you or someone you love has been diagnosed with severe aortic stenosis, you've likely heard two terms repeated in every conversation with your cardiologist: TAVR (transcatheter aortic valve replacement) and SAVR (surgical aortic valve replacement). You may have also been told — sometimes within minutes of your diagnosis — which one you should get.

As a board-certified cardiovascular and thoracic surgeon who has performed both procedures and reviewed hundreds of cases through second opinion consultations, I want to be direct with you: the choice between TAVR and SAVR is not as straightforward as it is sometimes presented. Both are excellent treatments. Neither is universally superior. And the right answer depends on factors specific to you — your anatomy, your age, your other medical conditions, and what matters most to you about your life after the procedure.

This article is my honest, evidence-based comparison of these two aortic valve replacement options. I wrote it for patients and families who want to understand the real tradeoffs — not a sales pitch for one approach over the other.

Understanding Aortic Stenosis Treatment: What Both Procedures Actually Do

Aortic stenosis is a narrowing of the aortic valve — the door between your heart's main pumping chamber and the rest of your body. When that valve becomes severely narrowed, the heart has to work dangerously hard to push blood through. Left untreated, severe symptomatic aortic stenosis carries a mortality rate exceeding 50% within two years. It is one of the clearest indications for intervention in all of cardiac surgery.

Both TAVR and SAVR solve the same problem, but they do it very differently:

• SAVR (Surgical Aortic Valve Replacement): A traditional open-heart operation. The surgeon makes an incision in the chest (a full sternotomy or, in select cases, a smaller partial sternotomy), places the patient on a heart-lung bypass machine, stops the heart, cuts out the diseased valve, and sews in a new one — either mechanical or bioprosthetic (tissue). This procedure has been performed successfully for over 60 years.
• TAVR (Transcatheter Aortic Valve Replacement): A catheter-based procedure, usually performed through a small puncture in the groin artery. A compressed bioprosthetic valve is threaded up to the heart and expanded inside the old, diseased valve, pushing it aside. The heart is not stopped. The chest is not opened. TAVR was first performed in humans in 2002 and received FDA approval in the United States starting in 2011.

On the surface, TAVR sounds like a clear winner. No open-heart surgery, shorter hospital stay, faster recovery. And for certain patients, it absolutely is the right choice. But medicine is rarely that simple, and the data — especially the long-term data — tells a more nuanced story.

What the Evidence Actually Shows: TAVR vs SAVR by Patient Risk Category

The landmark trials comparing TAVR and SAVR — the PARTNER series and the Evolut series — have shaped how we think about aortic stenosis treatment across different risk levels. Here is what we know, organized by the patient populations studied:

High-Risk and Inoperable Patients

This is where TAVR first proved itself. The PARTNER 1B trial showed that for patients too sick for open surgery, TAVR reduced mortality by 20% at one year compared to medical therapy alone. For high-surgical-risk patients, TAVR and SAVR showed similar survival outcomes at five years. The consensus is clear: TAVR is an excellent option for elderly, high-risk patients, and in many cases it is the preferred approach. ACC/AHA guidelines reflect this, recommending TAVR for patients aged 80 and older or those with high surgical risk.

Intermediate-Risk Patients

The PARTNER 2A and Evolut trials in intermediate-risk patients showed similar two-year outcomes between TAVR and SAVR. TAVR patients had shorter hospital stays and lower rates of bleeding and atrial fibrillation. SAVR patients had lower rates of vascular complications, paravalvular leak (blood leaking around the valve), and pacemaker implantation. At five years, outcomes remained broadly comparable, though some data suggested higher rates of valve reintervention in the TAVR group.

Low-Risk Patients — Where It Gets Complicated

The PARTNER 3 and Evolut Low Risk trials extended TAVR to younger, healthier patients and showed similar or favorable short-term results for TAVR. This led to rapid expansion of TAVR into lower-risk populations. However — and this is critical — we do not yet have 10- or 15-year durability data for TAVR valves in younger patients.

This matters enormously. A 55-year-old who receives a TAVR valve today may need that valve to last 25 or 30 years. We know surgical bioprosthetic valves can last 15 to 20 years or more. We know mechanical surgical valves can last a lifetime. We do not yet know whether TAVR valves will match that durability. Early signals from intermediate-term follow-up suggest structural valve deterioration may be more common in TAVR valves than in surgical bioprosthetic valves, though the data is still maturing.

In August 2024, the five-year results from the PARTNER 3 trial were presented, and while TAVR continued to perform well overall, the data reinforced the need for longer follow-up before drawing firm conclusions about TAVR's role in younger patients. The ACC/AHA guidelines currently recommend shared decision-making for patients younger than 65, with a preference toward SAVR for those expected to benefit from a mechanical valve or who have anatomy better suited to surgery.

Beyond Survival: Complications and Quality-of-Life Differences

When comparing aortic valve replacement options, survival data is only part of the picture. Several specific complications differ between TAVR and SAVR, and understanding them can change your decision:

• Permanent pacemaker implantation: TAVR carries a higher risk of requiring a permanent pacemaker — roughly 10-20% depending on the valve type and study, compared to 3-5% with SAVR. A pacemaker is not a catastrophe, but it is a lifelong implant with its own set of follow-up requirements and potential complications.
• Paravalvular leak: Because TAVR valves are deployed inside the old valve rather than sewn in, mild paravalvular leak is more common. In most cases this is clinically insignificant, but moderate or greater paravalvular leak is associated with worse long-term outcomes.
• Stroke: Early trials suggested slightly different stroke rates between the two procedures, but modern data shows the risk is low and relatively similar for both approaches — roughly 1-3%.
• Vascular complications: TAVR, because it requires threading a large catheter through your arteries, carries a higher risk of vascular injury — particularly in patients with small or heavily calcified arteries.
• Recovery time: This is where TAVR clearly wins. Most TAVR patients go home in one to three days and are back to normal activities within a week or two. SAVR requires a hospital stay of five to seven days and a recovery period of six to twelve weeks. For elderly patients or those with limited functional reserve, this difference can be significant.
• Atrial fibrillation: New-onset atrial fibrillation after surgery is considerably more common with SAVR (occurring in roughly 25-40% of patients) than with TAVR (roughly 5-10%). While often temporary, post-operative atrial fibrillation can increase the risk of stroke and prolong hospital stays.

If you want a more personalized estimate of your risk profile, our free cardiac surgery risk calculator can give you a starting point — though it is no substitute for expert review of your complete records.

Who Should Get TAVR? Who Should Get SAVR? A Practical Framework

Based on the current evidence and guidelines, here is how I think about this decision in my practice:

TAVR is likely the better choice if:

• You are 80 years old or older
• You have high or prohibitive surgical risk due to other medical conditions (severe lung disease, frailty, prior chest surgery, porcelain aorta)
• Your anatomy is favorable for transcatheter access
• You have isolated aortic stenosis without other conditions that would benefit from open surgery (such as significant coronary artery disease requiring bypass or mitral valve disease)

SAVR is likely the better choice if:

• You are younger than 65, especially if a mechanical valve (which avoids the durability question entirely) is an option you are willing to consider
• You have a bicuspid aortic valve — these valves have different anatomy that can make TAVR more challenging and may affect valve performance
• You need additional cardiac procedures at the same time — coronary artery bypass, mitral valve repair, aortic aneurysm repair, or atrial fibrillation surgery
• You have anatomy that is unfavorable for TAVR (small access vessels, heavy asymmetric calcification, low coronary arteries)
• You want the option of a mechanical valve to avoid future reintervention

The gray zone:

If you are between 65 and 80 with intermediate surgical risk, you are in the population where this decision requires the most careful thought. Both options are reasonable. The choice should be made through a genuine shared decision-making process — ideally with input from both a cardiac surgeon and an interventional cardiologist, which is the model recommended by the ACC/AHA guidelines through a multidisciplinary heart team.

This is also the group of patients who benefit most from getting an independent perspective. If you were given a recommendation by a single physician — especially one who only performs one of the two procedures — it is worth understanding whether the other option was truly considered. You can learn more about how our review process works and what an independent surgical assessment involves.

Questions You Should Ask Before Choosing Between TAVR and SAVR

Regardless of which direction you are leaning, I encourage every patient to ask their treatment team the following questions:

• Was my case discussed by a multidisciplinary heart team that included both a cardiac surgeon and an interventional cardiologist?
• What is the expected durability of the specific valve being recommended for me, and what happens if it fails in 10 or 15 years?
• What is my specific risk for pacemaker implantation, paravalvular leak, stroke, and vascular complications with the recommended approach?
• Are there any concomitant cardiac conditions (coronary artery disease, mitral regurgitation, atrial fibrillation, aortic aneurysm) that should be addressed at the same time?
• If I choose TAVR now, does that limit my options later? (This is especially important for younger patients, since TAVR inside a prior TAVR — so-called valve-in-valve — can be technically challenging depending on the initial valve size and coronary access.)
• What is this center's volume and outcomes data for the recommended procedure?

These are not confrontational questions. They are the questions that any surgeon or cardiologist who puts patients first will welcome.

Why a Second Opinion Matters for Aortic Valve Replacement Decisions

I want to be transparent about something that many patients don't realize: there are financial and structural incentives in medicine that can influence which procedure gets recommended. Hospitals and physicians are reimbursed differently for TAVR and SAVR. Programs that have invested heavily in TAVR infrastructure have volume targets. Cardiac surgeons who do not perform TAVR may default to recommending surgery. None of this means your doctor is acting in bad faith — the vast majority are not. But it means the system does not always guarantee that the recommendation you receive is the one most aligned with your individual anatomy, age, and goals.

An independent second opinion removes those structural influences. It gives you a fresh set of expert eyes on your imaging, your catheterization data, your CT angiography, your comorbidities, and your overall clinical picture — with no financial stake in the outcome.

If you are facing a decision between TAVR and SAVR — or if you have been told you need aortic valve replacement and want to be sure the recommended approach is the right one for your specific situation — a WhiteGloveMD second opinion can help. Our reviews are conducted by a board-certified cardiac surgeon, delivered in clear language you can understand, and designed to give you the confidence to move forward with the treatment plan that is truly best for you.